Dr T voiced his frustration and dissatisfaction with the ASX. Specifically that announcement reviewers are not knowledge enough in biotech to accurately determine if something is price sensitive, non price sensitive, or irrelevant. The catalyst for this being that the ASX had rejected the announcement of an independent study of Zantrene in Type 2 Diabetes.
The Hot Copper team permanent suspected Tillet's company rep account and eventually explained that it was because he had criticized the ASX.
Dr T voiced his frustration and dissatisfaction with the ASX....
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
